| pubmed-article:2462571 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0074825 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0026385 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:2462571 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:2462571 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2462571 | pubmed:dateCreated | 1989-2-9 | lld:pubmed |
| pubmed-article:2462571 | pubmed:abstractText | We previously demonstrated that supraphysiological insulin concentrations reduced the plasma 34K insulin-like growth factor-binding protein (IGF-BP) concentrations in humans. In this study we examined whether physiological changes in plasma insulin concentrations regulate IGF-BP and, if so, whether the regulation is influenced by race, glucose tolerance, or rate of glucose metabolism. For these purposes we 1) analyzed the relationship between fasting plasma insulin and IGF-BP concentrations in 2 racial groups (23 caucasians and 35 southwestern American Indians), 2) measured the response of plasma IGF-BP to oral glucose in 20 normal subjects, and 3) determined the dose-response characteristics of plasma IGF-BP to glucose and insulin in 23 normal subjects at 4 different insulin and glucose concentrations. The fasting plasma insulin concentration was inversely related to the plasma IGF-BP concentration in both the caucasian and Indian groups (P less than 0.0001). In the caucasian group the mean plasma IGF-BP concentration was higher [15 +/- 4 (+/- SE) micrograms/L] than in the Indian group (8 +/- 2 micrograms/L; P less than 0.05). This difference was independent of race and glucose tolerance, and it could be explained by lower plasma insulin concentrations in the caucasian (387 +/- 50 pmol/L) than in the Indian group (215 +/- 43 pmol/L; P less than 0.001). After oral glucose administration, the insulin concentration (423 +/- 72 pmol/L) was maximal 30 min after glucose treatment, and significant suppression of the IGF-BP concentration occurred at 90 min. Analysis of the dose-response curves revealed maximal suppression of IGF-BP at about 1150 pmol/L insulin, and half-maximal suppression at about 290 pmol/L. The plasma glucose concentration or the rate of glucose metabolism had no effect on the IGF-BP concentration. These data suggest that insulin is a major regulator of plasma IGF-BP concentrations under physiological conditions. | lld:pubmed |
| pubmed-article:2462571 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2462571 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2462571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2462571 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2462571 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:2462571 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:2462571 | pubmed:author | pubmed-author:SeppäläMM | lld:pubmed |
| pubmed-article:2462571 | pubmed:author | pubmed-author:KoivistoV AVA | lld:pubmed |
| pubmed-article:2462571 | pubmed:author | pubmed-author:Yki-JärvinenH... | lld:pubmed |
| pubmed-article:2462571 | pubmed:author | pubmed-author:KoistinenRR | lld:pubmed |
| pubmed-article:2462571 | pubmed:author | pubmed-author:SuikkariA MAM | lld:pubmed |
| pubmed-article:2462571 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2462571 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:2462571 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2462571 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2462571 | pubmed:pagination | 135-40 | lld:pubmed |
| pubmed-article:2462571 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:meshHeading | pubmed-meshheading:2462571-... | lld:pubmed |
| pubmed-article:2462571 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2462571 | pubmed:articleTitle | Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. | lld:pubmed |
| pubmed-article:2462571 | pubmed:affiliation | First Department of Obstetrics and Gynecology, University Central Hospital, Helsinki, Finland. | lld:pubmed |
| pubmed-article:2462571 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2462571 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2462571 | lld:pubmed |
